| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Urist Marshall | EVP, Research & Investments | C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK | /s/ Sean Weisberg, as Attorney-in-Fact, for Marshall Urist | 03 Dec 2025 | 0001838139 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RPRX | Class A Ordinary Shares | Sale | -$932K | -23.3K | -11.29% | $39.93 | 183K | 01 Dec 2025 | By Sandy Lamm LLC | F1, F2 |
| transaction | RPRX | Class A Ordinary Shares | Sale | -$728K | -18.2K | -41.57% | $39.90 | 25.6K | 01 Dec 2025 | Direct | F1, F3 |
| holding | RPRX | Class A Ordinary Shares | 19K | 01 Dec 2025 | By IRA |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 29, 2025. |
| F2 | The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.72 to $40.06 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F3 | The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.60 to $40.03 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
In addition to the holdings of Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP that are exchangeable into 2,474,120 Class A Ordinary Shares. The Reporting Person also holds 1,356,528 Class E Ordinary Shares of Royalty Pharma Holdings Ltd, certain of which are subject to vesting conditions and may, upon vesting, be converted into an equivalent number of Class A Ordinary Shares.